Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
Anti-obesity Effects of Dandelion (Taraxacum Officinale L.) in Premenopausal Obese Women: Impacts on Appetite, Energy Intake and Lipid Metabolism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Giza, Egypt, 12566
- October 6 university hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Premenopausal women with obesity. Age between 18-45 years Stable body weight in the past 3 months
Exclusion Criteria:
Pregnancy Breastfeeding Diabetes Cardiovascular diseases kidney or liver diseases use of medications that affect body weight Smoking Allergy to dandelion or related plants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control group
The Xenical group:60 patients will receive identical capsules of 120mg (one capsule) to be taken three times daily with meals and for 12 weeks, equaling 360mg total daily dose.
|
The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
|
|
Experimental: The dandelion extract group
The dandelion extract group: 60 patients will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals and for 12 weeks.
|
The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in body weight
Time Frame: monthly change, assessed up to 3 months
|
monthly change, assessed up to 3 months
|
|
Change in fat mass
Time Frame: Monthly change, assessed up to 3 months
|
Monthly change, assessed up to 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appetite Ratings
Time Frame: monthly change, assessed up to 3 months
|
monthly change, assessed up to 3 months
|
|
|
Dietary intake via 24-hour recalls
Time Frame: Recorded for patients daily, assessed up to 3 months
|
Recorded for patients daily, assessed up to 3 months
|
|
|
Lipid profile
Time Frame: Monthly change, assessed up to 3 months
|
Monthly change, assessed up to 3 months
|
|
|
CRP
Time Frame: Monthly change, assessed up to 3 months
|
C-reactive protein
|
Monthly change, assessed up to 3 months
|
|
TNF-α
Time Frame: Monthly change, assessed up to 3 months
|
Monthly change, assessed up to 3 months
|
|
|
IL-6
Time Frame: Monthly change, assessed up to 3 months
|
Interelukine 6
|
Monthly change, assessed up to 3 months
|
|
IL-16
Time Frame: Monthly change, assessed up to 3 months
|
Monthly change, assessed up to 3 months
|
|
|
Glycemic indices
Time Frame: Monthly change, assessed up to 3 months
|
Monthly change, assessed up to 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Dandelion effect on obesity
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.